1.
論文(リポジトリ) |
小山, 諭 ; 畠山, 勝義
概要:
The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent
…
of breast cancers, increasing the aggressiveness of the tumor. Trastuzumab (Herceptin^[○!R]), a recombinant monoclonal antibody against HER2 has been becoming a key drug for HER2-overexpressed breast cancer, moreover to be used in ajuvant and neoadjuvant settings.
続きを見る
|
|||||
2.
論文(リポジトリ) |
小杉, 伸一
概要:
Surgery is still a mainstay of treatment for esophageal cancer; however, the 5-year overall survival of patients who underwent esophagectomy with 3-field lymphadenectomy is 40-50%, which implies the limilation of surgery as a local
…
therapy. Since 1980s, the Japan Clinical Oncology Group) (JCOG) has conducted some multicenter randomized controlled trials to stablish a standard adjuvant therapy for this disease. Some representative JCOG studies and our relevant clinical studies are introduced and future perspectives are also discussed in this review.
続きを見る
|